Silence TherapeuticsSLN 44 FCF Margin % is -3,697.39% as of Mar. 2026. GuruFocus rates SLN with a GF Score™ of 44/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, Silence Therapeutics ranks worse than 93.13% on this metric.
The historical rank and industry rank for Silence Therapeutics's FCF Margin % or its related term are showing as below:
SLN'
s FCF Margin % Range Over the Past 10 Years
Min: -60027.27 Med: -206.05 Max: 703.75
Current: -7820.74
During the past 13 years, the highest FCF Margin % of Silence Therapeutics was 703.75%. The lowest was -60027.27%. And the median was -206.05%.
SLN's FCF Margin % is ranked worse than 93.13% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs SLN: -7820.74
Silence Therapeutics FCF Margin % Related Terms
Silence Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Silence Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Silence Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silence Therapeutics (SLN) has a FCF Margin % of -3,697.39% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Silence Therapeutics and its competitors. According to the industry distribution chart, Silence Therapeutics ranks #894 out of 960 companies in the Biotechnology industry, placing it in the top 93.1%.
Is Silence Therapeutics' FCF Margin % too high?
Silence Therapeutics' current FCF Margin % is -3,697.39%. Based on the distribution chart, Silence Therapeutics ranks #894 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Silence Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' FCF Margin % compare to CRBP and TTRX?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #894 out of 960 companies for FCF Margin %. This places Silence Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Silence Therapeutics and its competitors. Silence Therapeutics's current FCF Margin % is -3,697.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $9.16 — trading 4261.9% above its estimated fair value. The current FCF Margin % is -3,697.39%. Silence Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current FCF Margin % is -3,697.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (SLN) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of $9.16 is trading 4261.9% above its estimated GF Value™ of $0.21.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for SLN:
FCF Margin %: -3,697.39%
GF Value™: $0.21 vs. price of $9.16 (4261.9% above fair value)
No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
44GF Score
Get the complete analysis for SLN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLN has been successfully added to your 
